ATE272117T1 - Rekombinante zellen der monozyten-makrophagen zelllinie zur gen-therapie - Google Patents

Rekombinante zellen der monozyten-makrophagen zelllinie zur gen-therapie

Info

Publication number
ATE272117T1
ATE272117T1 AT94925523T AT94925523T ATE272117T1 AT E272117 T1 ATE272117 T1 AT E272117T1 AT 94925523 T AT94925523 T AT 94925523T AT 94925523 T AT94925523 T AT 94925523T AT E272117 T1 ATE272117 T1 AT E272117T1
Authority
AT
Austria
Prior art keywords
monocyte
cell line
gene therapy
recombinant cells
macrophage cell
Prior art date
Application number
AT94925523T
Other languages
English (en)
Inventor
Hedi Haddada
Manuel Lopez
Michel Perricaudet
Original Assignee
Aventis Pharma Sa
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa, Inst Nat Sante Rech Med filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE272117T1 publication Critical patent/ATE272117T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT94925523T 1993-08-25 1994-08-22 Rekombinante zellen der monozyten-makrophagen zelllinie zur gen-therapie ATE272117T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9310222A FR2709309B1 (fr) 1993-08-25 1993-08-25 Compositions cellulaires, préparation et utilisations thérapeutiques.
PCT/FR1994/001019 WO1995006120A1 (fr) 1993-08-25 1994-08-22 Cellules recombinantes de la lignee monocyte-macrophage pour la therapie genique

Publications (1)

Publication Number Publication Date
ATE272117T1 true ATE272117T1 (de) 2004-08-15

Family

ID=9450378

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94925523T ATE272117T1 (de) 1993-08-25 1994-08-22 Rekombinante zellen der monozyten-makrophagen zelllinie zur gen-therapie

Country Status (14)

Country Link
US (1) US6210963B1 (de)
EP (1) EP0719332B1 (de)
JP (1) JP3731035B2 (de)
KR (1) KR100392984B1 (de)
AT (1) ATE272117T1 (de)
AU (1) AU698043B2 (de)
CA (1) CA2170159A1 (de)
DE (1) DE69433921T2 (de)
FI (1) FI960855A7 (de)
FR (1) FR2709309B1 (de)
IL (1) IL110754A (de)
NO (1) NO319990B1 (de)
WO (1) WO1995006120A1 (de)
ZA (1) ZA946264B (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6734014B1 (en) 1996-02-08 2004-05-11 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for transforming dendritic cells and activating T cells
JP2000505650A (ja) * 1996-02-08 2000-05-16 アメリカ合衆国 樹状突起細胞を形質転換し、そしてｔ細胞を活性化するための方法及び組成物
FR2746109B1 (fr) 1996-03-12 1998-04-17 Rhone Poulenc Rorer Sa Milieu pour la conservation de materiel biologique
JP2001501944A (ja) * 1996-10-09 2001-02-13 オックスフォード バイオメディカ（ユーケイ）リミテッド 治療薬のデリバリーにおける単核食細胞
US20020068048A1 (en) * 1997-09-05 2002-06-06 Patrick A. Dreyfus Method for the treatment or diagnosis of human pathologies with disseminated or difficult to access cells or tissues
CA2303663A1 (en) * 1997-09-23 1999-04-01 Oxford Biomedica (Uk) Limited Expression of genes in hematopoietic stem cells in hischaemic conditions
WO2000060054A1 (en) * 1999-04-06 2000-10-12 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Pharmaceutical compositions comprising circulating blood cells, preferably monocytes and uses thereof
AU2001261737A1 (en) * 2000-05-18 2001-11-26 Genetix Pharmaceuticals, Inc. Methods and compositions for promoting angiogenesis using monocytes
US6579522B1 (en) 2000-06-27 2003-06-17 Genvec, Inc. Replication deficient adenoviral TNF vector
CN1388248A (zh) * 2001-05-25 2003-01-01 钱其军 高效表达干扰素的肿瘤细胞内特异性增殖的腺病毒及其构建方法
AU2002341717A1 (en) * 2001-09-17 2003-04-01 Medcell Biologics, Llc. Cell therapy system
US20030086903A1 (en) 2001-11-02 2003-05-08 Genvec, Inc. Therapeutic regimen for treating cancer
AU2003203527A1 (en) * 2002-04-12 2003-10-30 Sumitomo Electric Industries, Ltd. Control of the ratio of lap to lip
JP4754219B2 (ja) * 2002-12-02 2011-08-24 アムジエン・フレモント・インコーポレイテツド 腫瘍壊死因子を対象とする抗体、およびそれらの使用
EP2241330A1 (de) 2003-02-14 2010-10-20 The Curators Of The University Of Missouri Empfängnisverhütende Verfahren und Zusammensetzungen betreffend proteasomale Störung
US20080038234A1 (en) * 2004-03-23 2008-02-14 Shuji Hayashi Bone Marrow-Related Cells Associated With Tissue Maintenance And/Or Repair
US7838503B2 (en) * 2005-06-15 2010-11-23 Children's Medical Center Corporation Methods for extending the replicative lifespan of cells
CN101548008B (zh) 2006-10-04 2013-04-17 詹森药业有限公司 失活的人工抗原提呈细胞的制备及其在细胞疗法中的用途
PL2106440T3 (pl) * 2007-01-12 2016-02-29 Univ Illinois Komórki niepochodzące od małp do hodowli wirusa zespołu rozrodczo-oddechowego świń (PRRS)
JP5546107B2 (ja) * 2008-04-17 2014-07-09 国立大学法人宇都宮大学 ＲＮＡウイルスＢｍＭＬＶ陰性カイコ培養細胞株
EP2248903A1 (de) * 2009-04-29 2010-11-10 Universitat Autònoma De Barcelona Verfahren und Reagenzien zum effizienten und gezielten Gentransfer in Monozyten und Makrophagen
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
ES2667425T3 (es) 2011-06-10 2018-05-10 Oregon Health & Science University Glucoproteínas y vectores recombinantes de CMV
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2586461A1 (de) 2011-10-27 2013-05-01 Christopher L. Parks Von einem eingehüllten Virus abgeleitete Virenpartikel
EP2679596B1 (de) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 Env-proteinvariante
EP3461491B1 (de) 2013-04-18 2024-11-13 TILT Biotherapeutics Oy Verbesserte adoptive zelltherapie
US12421502B2 (en) 2013-04-18 2025-09-23 Tilt Biotherapeutics Oy Enhanced adoptive cell therapy
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (de) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (de) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
IL260987B2 (en) 2016-02-04 2024-09-01 Zhenglun Zhu Treatment and diagnosis of inflammatory disorders
WO2018183447A1 (en) * 2017-03-28 2018-10-04 Zhenglun Zhu Methods of treating neoplastic diseases
EP3876977A1 (de) 2018-11-06 2021-09-15 The Regents Of The University Of California Chimäre antigen-rezeptoren für phagocytose
US11026973B2 (en) 2019-04-30 2021-06-08 Myeloid Therapeutics, Inc. Engineered phagocytic receptor compositions and methods of use thereof
WO2021046243A2 (en) 2019-09-03 2021-03-11 Myeloid Therapeutics, Inc. Methods and compositions for genomic integration
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
EP4240367A4 (de) 2020-11-04 2024-10-16 Myeloid Therapeutics, Inc. Manipulierte chimäre fusionsproteinzusammensetzungen und verfahren zur verwendung davon
KR20240013094A (ko) 2021-03-17 2024-01-30 마이얼로이드 테라퓨틱스, 인크. 조작된 키메라 융합 단백질 조성물 및 그의 사용 방법
JP2024512808A (ja) 2021-04-05 2024-03-19 ヤンセン バイオテツク，インコーポレーテツド Ｃａｌｒ及びｊａｋ２ｔ細胞受容体
WO2022241029A1 (en) 2021-05-11 2022-11-17 Myeloid Therapeutics, Inc. Methods and compositions for genomic integration
CN114657143B (zh) * 2022-03-11 2022-10-25 西安电子科技大学 一种肿瘤微环境调控型car-单核/巨噬细胞及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989005349A1 (en) * 1987-12-09 1989-06-15 The Australian National University Method of combating viral infections
US5399493A (en) * 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
CA1340565C (en) * 1989-06-29 1999-05-25 Thomas B. Okarma Device and process for cell capture and recovery
US5246921A (en) * 1990-06-26 1993-09-21 The Wistar Institute Of Anatomy And Biology Method for treating leukemias
FR2683725B1 (fr) * 1991-11-15 1995-07-07 Pasteur Institut Composition cellulaire pour le traitement des organismes humains ou animaux.
WO1993009815A1 (en) * 1991-11-22 1993-05-27 The General Hospital Corporation Specific tolerance in transplantation
US5338165A (en) * 1991-11-25 1994-08-16 Ford Motor Company Automotive fuel pump with modular pump housing
GB9125623D0 (en) * 1991-12-02 1992-01-29 Dynal As Cell modification
US5436151A (en) * 1992-04-03 1995-07-25 Regents Of The University Of Minnesota Method for culturing human hematopoietic stem cells in vitro
DE4219626A1 (de) * 1992-06-16 1993-12-23 Wehling Peter Priv Doz Dr Med Methode zur Einschleusung therapeutisch relevanter Gene in Körperzellen
AU692152B2 (en) * 1993-03-17 1998-06-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Immunogenic chimeras comprising nucleic acid sequences encoding endoplasmic reticulum signal sequence peptides and at least one other peptide, and their uses in vaccines and disease treatments
US5543328A (en) * 1993-08-13 1996-08-06 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
AU5297496A (en) * 1995-02-17 1996-09-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods of preparation and use of recombinant adenoviral vectors

Also Published As

Publication number Publication date
NO960743L (no) 1996-03-25
AU7539894A (en) 1995-03-21
IL110754A0 (en) 1994-11-11
EP0719332A1 (de) 1996-07-03
AU698043B2 (en) 1998-10-22
WO1995006120A1 (fr) 1995-03-02
FR2709309A1 (fr) 1995-03-03
US6210963B1 (en) 2001-04-03
CA2170159A1 (fr) 1995-03-02
DE69433921D1 (de) 2004-09-02
FI960855A0 (fi) 1996-02-23
EP0719332B1 (de) 2004-07-28
JPH09501837A (ja) 1997-02-25
FI960855L (fi) 1996-04-23
NO960743D0 (no) 1996-02-23
ZA946264B (en) 1995-03-20
DE69433921T2 (de) 2006-10-05
IL110754A (en) 2001-04-30
FI960855A7 (fi) 1996-04-23
JP3731035B2 (ja) 2006-01-05
FR2709309B1 (fr) 1995-11-10
NO319990B1 (no) 2005-10-10
KR100392984B1 (ko) 2004-10-20

Similar Documents

Publication Publication Date Title
AU698043B2 (en) Recombinant cells from the monocyte-macrophage cell line for gene therapy
Lu et al. Alterations at the rel locus in human lymphoma
TR199801395A2 (xx) Genetik olarak de�i�tirilmi� h�creler ve bunlar�n kullan�mlar�.
AR056723A2 (es) Polipeptido purificado metodo para producirlo , metodo para identificarlo y/ o aislarlo composicion farmaceutica que lo comprende, secuencia de acidos nucleicos aislada que codifica dicho polipeptido, vector que contiene a dicha secuencia celula huesped transfectada por dicho vector, sonda nucleotid
DE69837393D1 (de) Stimulierung von hämatopoietischen zellen im vitro
ATE265219T1 (de) Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten
UA66417C2 (en) Recombinant adenovirus affecting canines, pharmaceutical composition
EP0653940A4 (de) Glialmitogene faktoren, ihre herstellung und verwendung.
BR9405507A (pt) Adenovirus recombinante defeituoso linhagem celular e composição farmaceutica
DE69527540D1 (de) Verwendung von stammzellenfaktor und löslichen interleukin-6-rezeptor zur vermehrung der hämatopoietischen vorläuferzellen
DE59903410D1 (de) Hybridprotein zur hemmung der mastzelldegranulation und dessen verwendung
ATE361668T1 (de) Kombinierte tumor suppressor-gen-therapie und chemotherapie bei der neoplasmabehandlung
Van Zeebroeck et al. Fast and efficient genome editing of human FOXP3+ regulatory T cells
Facchetti et al. Functional and molecular characterization of tumour-infiltrating lymphocytes and clones thereof from a major-histocompatibility-complex-negative human tumour: neuroblastoma
BR0010563A (pt) Composições isoladas de células da pele e métodos para seu uso
Yu et al. Mechanism study of ubiquitination in T cell development and autoimmune disease
AU687623B2 (en) Cell Adhesion peptides for use in modifying mutual adhesion among eukaryotic cells
DE69903559D1 (de) Verwendung von neuen zelltod inducierenden mitteln im synergismus mit interferon
EP0160486A3 (en) Monoclonal antibodies
ATE144791T1 (de) Innerhalb des alpha-locus gelegenes t-zell- rezeptor-gen und dna-konstruktionen
DE69328832D1 (de) Zielelektrode zur verhinderung von korrision in elektrochemischen zellen
BR9407357A (pt) Novos tripeptideos utilizáveis em terapia cns e imune
SE8605459D0 (sv) Novel cell growth regulatory factor
NZ332482A (en) Human and clam cyclin-selective ubiquitin carrier polypeptides (E2) that are involved in the ubiquitination of cyclins A and B, inhibitors of these E2 polypeptides are included
Haughn Tumor Cell Growth Arrest Caused by

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties